熱門資訊> 正文
国防部批准Symvess上市，Humacyte股价上涨
2025-07-08 21:53
- Shares of Humacyte (NYSE:HUM) traded ~16% higher on Tuesday after the U.S. Defense Logistics Agency issued an Electronic Catalog (ECAT) listing approval for its vascular repair product Symvess, making it more readily accessible for patients.
- ECAT is an internet solution through which commercial catalogs of multiple manufacturers and distributors are available at discounted prices for the DoD and other federal agencies.
- The decision is expected to make Symvess readily accessible for patients under the care of DOD and U.S. Department of Veterans Affairs facilities.
- “We are pleased that Symvess is now listed in the ECAT system, making the product more readily available to healthcare professionals treating military personnel and their families,” Humacyte (NYSE:HUM) CEO Laura Niklason remarked.
- In December, the FDA approved the bioengineered product for certain adults with arterial injury in the extremities.
More on Humana
- Humana: Margin Over Volume Signals A Buy
- Humana: Implied Volatility Creating A Viable Investment Case
- Humana, Inc. (HUM) Q1 2025 Earnings Call Transcript
- Humana's CenterWell to buy The Villages Health amid chapter 11 bankruptcy
- Novo Nordisk taps WeightWatchers for Wegovy after exiting Hims & Hers deal
推薦文章
華盛早報 | 就在今日！九三閲兵即將盛大開啟；特朗普對美聯儲下狠手，黃金漲破3600美元再創新高
卡夫亨氏拆分計劃惹怒巴菲特 穆迪警告或下調其投資級評級
谷歌贏得重大勝利，美法官裁決其無需剝離Chrome瀏覽器和安卓系統
美股收盤：三大指數齊跌！標普500跌0.69%，納指跌0.82%，英偉達跌近2%
9月3日外盤頭條：特朗普稱將就全球關税案裁決提起上訴 谷歌無需出售Chrome瀏覽器 特朗普否認健康不佳傳聞
美股機會日報 | 三大指數期貨集體走低，納指期貨跌近1%；蔚來一度重挫超17%
一圖看懂 | 蔚來Q2經調整淨虧損同比收窄9%！三季度交付及營收指引創新高
9月2日外盤頭條：特朗普或在今秋宣佈住房緊急狀態 雀巢CEO職場緋聞曝光被裁 谷歌駁斥有關Gmail重大安全警報
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
